Compare Stocks

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDTX Cidara Therapeutics	$0.69 -5.0%	$0.78	$0.59 ▼ $1.48	$62.17M	0.98	652,517 shs	333,175 shs
CRTX Cortexyme	$1.06 +6.0%	$1.19	$1.78 ▼ $40.66	$31.96M	1.4	620,672 shs	80,582 shs
FRLN Freeline Therapeutics	$6.48	$6.48	$2.11 ▼ $8.74	$28.12M	0.66	12,055 shs	N/A
RUBY Rubius Therapeutics	$0.06 +2.7%	$0.04	$0.00 ▼ $0.38	$5.16M	2.59	1.15 million shs	755,800 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDTX Cidara Therapeutics	-0.03%	-16.44%	+1.09%	+0.87%	-35.54%
CRTX Cortexyme	+6.00%	+6.00%	-10.92%	-21.48%	-28.38%
FRLN Freeline Therapeutics	0.00%	0.00%	0.00%	+1.25%	+4.10%
RUBY Rubius Therapeutics	0.00%	0.00%	0.00%	0.00%	+171.43%

SHOCKING Crypto Leak… (Ad)

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CDTX Cidara Therapeutics	3.6988 of 5 stars	3.5	3.0	0.0	4.6	2.4	0.8	0.0
CRTX Cortexyme	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FRLN Freeline Therapeutics	0.0435 of 5 stars	1.0	0.0	0.0	0.0	0.0	0.8	1.3
RUBY Rubius Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CDTX Cidara Therapeutics	3.00	Buy	$4.67	580.27% Upside
CRTX Cortexyme	N/A	N/A	N/A	N/A
FRLN Freeline Therapeutics	2.00	Hold	$4.83	-25.41% Downside
RUBY Rubius Therapeutics	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest RUBY, CDTX, CRTX, and FRLN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
4/8/2024	CDTX Cidara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CDTX Cidara Therapeutics	$64.29M	0.97	N/A	N/A	($0.04) per share	-17.15
CRTX Cortexyme	N/A	N/A	N/A	N/A	$3.97 per share	N/A
FRLN Freeline Therapeutics	N/A	N/A	N/A	N/A	$12.07 per share	N/A
RUBY Rubius Therapeutics	N/A	N/A	N/A	N/A	$0.17 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CDTX Cidara Therapeutics	-$29.80M	-$0.39	N/A	N/A	N/A	-55.49%	-264.84%	-48.12%	5/9/2024 (Estimated)
CRTX Cortexyme	-$89.94M	-$2.97	N/A	N/A	N/A	N/A	-70.96%	-63.53%	N/A
FRLN Freeline Therapeutics	-$88.97M	-$5.59	N/A	N/A	N/A	N/A	-150.46%	-97.01%	N/A
RUBY Rubius Therapeutics	-$179.67M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
CRTX Cortexyme	N/A	N/A	N/A	N/A	N/A
FRLN Freeline Therapeutics	N/A	N/A	N/A	N/A	N/A
RUBY Rubius Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CDTX Cidara Therapeutics	N/A	1.62	1.55
CRTX Cortexyme	N/A	9.92	9.92
FRLN Freeline Therapeutics	N/A	1.95	N/A
RUBY Rubius Therapeutics	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
CDTX Cidara Therapeutics	35.82%
CRTX Cortexyme	63.18%
FRLN Freeline Therapeutics	46.26%
RUBY Rubius Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
CDTX Cidara Therapeutics	7.43%
CRTX Cortexyme	27.90%
FRLN Freeline Therapeutics	1.90%
RUBY Rubius Therapeutics	5.30%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CDTX Cidara Therapeutics	73	90.62 million	83.89 million	Optionable
CRTX Cortexyme	55	30.15 million	21.74 million	Not Optionable
FRLN Freeline Therapeutics	152	4.34 million	4.26 million	Not Optionable
RUBY Rubius Therapeutics	6	90.48 million	85.69 million	Not Optionable

RUBY, CDTX, CRTX, and FRLN Headlines

Source	Headline
	Vacant Rubius property generating interest after 1 year on market pbn.com - April 18 at 1:01 AM
	Sensorium Therapeutics Appoints Sam Rasty as Chief Business Officer citizentribune.com - April 17 at 8:01 PM
	Vacant RI biotech space, once owned by Rubius Therapeutics, offered at 'deeply discounted price' bizjournals.com - March 11 at 5:07 PM
	Rubius Therapeutics Inc RUBY morningstar.com - November 5 at 8:39 PM
	‘Like playing the lottery’: Laid-off life sciences workers give a snapshot of a cooling-down sector bostonglobe.com - October 16 at 7:58 AM
	Ruby Dunne Biography & Movies tribute.ca - September 22 at 6:08 PM
	Parenting Vlogger Ruby Franke Held Without Bail on Child Abuse Charges oxygen.com - September 14 at 8:44 PM
	YouTuber mom Ruby Franke arrested and charged in child abuse investigation: What to know today.com - September 8 at 6:33 PM
	Ruby Gonzales dailynews.com - August 21 at 8:30 AM
	RUBY - Rubius Therapeutics, Inc. uk.finance.yahoo.com - August 2 at 2:37 AM
	North American Morning Briefing: Alphabet, -2- morningstar.com - July 25 at 7:07 AM
	Ruby Rivera, 23ABC turnto23.com - July 1 at 12:54 AM
	Ruby Speaking comedy.co.uk - June 23 at 3:11 PM
	Rubius Therapeutics Outlines Dissolution Plan, After Unsuccessful Attempt On Alternatives finance.yahoo.com - March 2 at 1:59 AM
	Whatever happened to Ruby? infoworld.com - February 17 at 4:07 PM
	Thinking about buying stock in Sorrento Therapeutics, Rubius Therapeutics, Ideanomics, SoundHound AI, or C3.ai? marketwatch.com - February 14 at 7:55 PM
	Why Is Rubius Therapeutics (RUBY) Stock Up 35% Today? msn.com - February 14 at 9:54 AM
	The Wrap: Ruby's moving to Congress Street, launching new French concept yahoo.com - January 25 at 4:27 AM
	Ruby Wax sparks concern from fans after posting video from hospital bed mirror.co.uk - January 12 at 12:51 AM
	Ruby Wax sparks concern amongst fans with her latest appearance from a hospital bed promoting book dailymail.co.uk - January 12 at 12:51 AM
	Former Rubius CEO jumps to another Flagship spinout finance.yahoo.com - November 18 at 10:30 AM
	Rubius Therapeutics lays off most of its staff, explores sale finance.yahoo.com - November 4 at 12:16 PM
	Rubius Therapeutics Cuts Almost 85% Of Its Workforce, Starts Looking For Strategic Alternatives finance.yahoo.com - November 3 at 1:47 PM
	A high flyer out of Flagship implodes — for the last time endpts.com - November 2 at 5:41 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Cidara Therapeutics

NASDAQ:CDTX

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Cortexyme

NASDAQ:CRTX

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Freeline Therapeutics

NASDAQ:FRLN

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Rubius Therapeutics

NASDAQ:RUBY

Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial